LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more
LIWANLI Innovation Co Ltd (3054) - Net Assets
Latest net assets as of June 2025: NT$743.29 Million TWD
Based on the latest financial reports, LIWANLI Innovation Co Ltd (3054) has net assets worth NT$743.29 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$776.15 Million) and total liabilities (NT$32.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$743.29 Million |
| % of Total Assets | 95.77% |
| Annual Growth Rate | 1.77% |
| 5-Year Change | -19.56% |
| 10-Year Change | -30.96% |
| Growth Volatility | 29.39 |
LIWANLI Innovation Co Ltd - Net Assets Trend (2003–2024)
This chart illustrates how LIWANLI Innovation Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LIWANLI Innovation Co Ltd (2003–2024)
The table below shows the annual net assets of LIWANLI Innovation Co Ltd from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$752.96 Million | -3.90% |
| 2023-12-31 | NT$783.51 Million | +2.37% |
| 2022-12-31 | NT$765.36 Million | -14.73% |
| 2021-12-31 | NT$897.52 Million | -4.11% |
| 2020-12-31 | NT$936.03 Million | -3.08% |
| 2019-12-31 | NT$965.79 Million | -5.76% |
| 2018-12-31 | NT$1.02 Billion | -33.21% |
| 2017-12-31 | NT$1.53 Billion | +1.42% |
| 2016-12-31 | NT$1.51 Billion | +38.72% |
| 2015-12-31 | NT$1.09 Billion | -11.91% |
| 2014-12-31 | NT$1.24 Billion | -10.18% |
| 2013-12-31 | NT$1.38 Billion | +83.02% |
| 2012-12-31 | NT$753.19 Million | -5.80% |
| 2011-12-31 | NT$799.59 Million | -10.69% |
| 2010-12-31 | NT$895.33 Million | -20.23% |
| 2009-12-31 | NT$1.12 Billion | +68.35% |
| 2008-12-31 | NT$666.68 Million | +0.86% |
| 2007-12-31 | NT$661.02 Million | -3.44% |
| 2006-12-31 | NT$684.56 Million | +47.86% |
| 2005-12-31 | NT$462.99 Million | +21.13% |
| 2004-12-31 | NT$382.24 Million | -26.57% |
| 2003-12-31 | NT$520.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LIWANLI Innovation Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 217.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$836.91 Million | 111.15% |
| Total Equity | NT$752.96 Million | 100.00% |
LIWANLI Innovation Co Ltd Competitors by Market Cap
The table below lists competitors of LIWANLI Innovation Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ildong Holdings Co Ltd
KO:000230
|
$49.55 Million |
|
Nitratos de Chile SA
SN:NITRATOS
|
$49.57 Million |
|
BABYTREE GROUP
F:BTR
|
$49.60 Million |
|
Daaz Bara Lestari Tbk
JK:DAAZ
|
$49.60 Million |
|
Votum SA
WAR:VOT
|
$49.55 Million |
|
Nebag ag
SW:NBEN
|
$49.55 Million |
|
Pruksa Holding Public Company Limited
BK:PSH
|
$49.54 Million |
|
Yuhwa Securities Co Ltd
KO:003465
|
$49.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIWANLI Innovation Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 783,513,000 to 752,957,000, a change of -30,556,000 (-3.9%).
- Net loss of 32,074,000 reduced equity.
- Other comprehensive income increased equity by 29,612,000.
- Other factors decreased equity by 28,094,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-32.07 Million | -4.26% |
| Other Comprehensive Income | NT$29.61 Million | +3.93% |
| Other Changes | NT$-28.09 Million | -3.73% |
| Total Change | NT$- | -3.90% |
Book Value vs Market Value Analysis
This analysis compares LIWANLI Innovation Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.49x to 9.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$19.46 | NT$87.30 | x |
| 2010-12-31 | NT$15.46 | NT$87.30 | x |
| 2011-12-31 | NT$13.86 | NT$87.30 | x |
| 2012-12-31 | NT$13.06 | NT$87.30 | x |
| 2013-12-31 | NT$18.30 | NT$87.30 | x |
| 2014-12-31 | NT$15.51 | NT$87.30 | x |
| 2015-12-31 | NT$13.61 | NT$87.30 | x |
| 2016-12-31 | NT$16.63 | NT$87.30 | x |
| 2017-12-31 | NT$12.95 | NT$87.30 | x |
| 2018-12-31 | NT$10.26 | NT$87.30 | x |
| 2019-12-31 | NT$11.58 | NT$87.30 | x |
| 2020-12-31 | NT$11.22 | NT$87.30 | x |
| 2021-12-31 | NT$10.86 | NT$87.30 | x |
| 2022-12-31 | NT$9.49 | NT$87.30 | x |
| 2023-12-31 | NT$9.71 | NT$87.30 | x |
| 2024-12-31 | NT$9.34 | NT$87.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LIWANLI Innovation Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -32.35%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.05x
- Recent ROE (-4.26%) is below the historical average (1.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 6.31% | 2.81% | 0.94x | 2.40x | NT$-19.23 Million |
| 2008 | 3.80% | 4.86% | 0.67x | 1.17x | NT$-41.37 Million |
| 2009 | 7.74% | 6.98% | 1.01x | 1.10x | NT$-25.42 Million |
| 2010 | 13.10% | 11.51% | 0.99x | 1.15x | NT$27.75 Million |
| 2011 | 4.48% | 1.54% | 1.88x | 1.55x | NT$-44.18 Million |
| 2012 | -7.72% | -2.13% | 1.85x | 1.97x | NT$-133.47 Million |
| 2013 | 21.02% | 11.86% | 1.14x | 1.55x | NT$151.93 Million |
| 2014 | 1.24% | 0.68% | 1.17x | 1.55x | NT$-108.51 Million |
| 2015 | -9.49% | -12.39% | 0.50x | 1.52x | NT$-212.52 Million |
| 2016 | 4.15% | 19.44% | 0.19x | 1.15x | NT$-88.49 Million |
| 2017 | 5.34% | 23.52% | 0.22x | 1.05x | NT$-71.53 Million |
| 2018 | 0.09% | 0.48% | 0.17x | 1.04x | NT$-101.59 Million |
| 2019 | 0.29% | 2.14% | 0.11x | 1.17x | NT$-93.80 Million |
| 2020 | -1.45% | -4.92% | 0.28x | 1.07x | NT$-107.22 Million |
| 2021 | 5.08% | 95.29% | 0.05x | 1.06x | NT$-44.19 Million |
| 2022 | -15.80% | -355.73% | 0.04x | 1.05x | NT$-197.44 Million |
| 2023 | 0.65% | 13.12% | 0.05x | 1.06x | NT$-73.25 Million |
| 2024 | -4.26% | -32.35% | 0.13x | 1.05x | NT$-107.37 Million |
Industry Comparison
This section compares LIWANLI Innovation Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,942,771,444
- Average return on equity (ROE) among peers: 3.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIWANLI Innovation Co Ltd (3054) | NT$743.29 Million | 6.31% | 0.04x | $49.55 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |